Elicio Therapeutics Stock Falls Following $15M Direct Offering

By EC Assets · Published 2 July 2026

Elicio Therapeutics Inc. shares declined Thursday after the company announced a $15 million registered direct offering. The offering is expected to close on or about July 6, 2026. Gross proceeds from the offering will be used to fund the clinical development of ELI-002, a treatment for metastatic. The clinical-stage biotechnology company entered into a securities purchase agreement for the offering. Approximately 4.38 million shares are being sold in the offering. Elicio Therapeutics priced these shares at about $3.43 each. Two new institutional investors are leading the offering. An existing shareholder is also participating. The closing of the offering is subject to customary conditions. Elicio Therapeutics' stock fell 32.5% Thursday. Shares plunged over 24% premarket on Thursday. The company initiated the registered direct offering on July 2, 2026. This article is intended for informational purposes only. It does not constitute investment advice.